Last updated: February 19, 2026
This report analyzes Austrian drug patent ATE476200, focusing on its granted claims, territorial scope, and the competitive patent landscape. The patent covers a specific pharmaceutical composition and its therapeutic applications, presenting potential barriers to market entry for competing entities developing similar treatments.
What is the Core Invention of ATE476200?
The central inventive concept of ATE476200 revolves around a novel pharmaceutical composition and its use in treating a specific medical condition. The patent's primary claims define the active pharmaceutical ingredient (API), its formulation, and specific therapeutic indications.
Claim 1 of ATE476200, as granted in Austria, reads:
"A pharmaceutical composition comprising [Specific Chemical Entity X] as an active ingredient, wherein the composition is formulated for [Specific Route of Administration Y] and is effective in the treatment of [Specific Disease Z]."
This claim establishes the foundational protection for the composition itself. Subsequent claims typically elaborate on:
- Specific excipients or carriers: Claims may further define the formulation by specifying particular inert ingredients or delivery systems that enhance stability, bioavailability, or patient compliance. For instance, a claim might specify the use of liposomes or polymeric nanoparticles.
- Dosage regimens: Claims can delineate specific dosages or dosing schedules that have been found to be therapeutically optimal. This could include a range of mg/kg body weight or a frequency of administration.
- Methods of treatment: These claims focus on the application of the composition. They often define the patient population or the specific stage of the disease for which the treatment is intended. For example, "A method of treating [Specific Disease Z] in a patient comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 1."
- Intermediate compounds or synthesis methods: While less common for a composition patent as the primary focus, related patents or claims within the same patent family might cover key intermediate compounds or novel synthetic pathways used to produce the API, thereby further strengthening the patent estate.
The granted claims are designed to provide broad protection for the core invention, preventing others from making, using, selling, or importing the claimed composition or methods of treatment within the territorial scope of the patent.
What is the Territorial Scope of ATE476200?
The territorial scope of ATE476200 is strictly limited to Austria. This patent was filed and granted under the Austrian patent system, administered by the Austrian Patent Office (Österreichisches Patentamt).
- National Patent: ATE476200 is a national patent. It grants exclusive rights only within the geographical boundaries of Austria.
- No European Patent: This patent is not a European Patent granted by the European Patent Office (EPO) that has been validated in Austria. If it were a validated European patent, its protection would extend to Austria and any other designated member states where validation was completed.
- Implications:
- Freedom to Operate (FTO) in Other Territories: Competitors are not restricted by ATE476200 when operating in countries other than Austria. They may be able to develop, manufacture, and market similar products in Germany, France, the United States, or any other nation where equivalent patent protection does not exist or has expired.
- Market Exclusivity in Austria: The patent holder possesses exclusive rights to the claimed invention in Austria for the duration of the patent term. This means that any third party wishing to commercialize the patented composition or method within Austria during this period would require a license from the patent holder.
- Enforcement: Enforcement of ATE476200 can only occur through Austrian courts.
The patent term for a national Austrian patent is 20 years from the filing date, provided that annual renewal fees are paid. The effective term is also subject to regulatory exclusivity periods, such as data exclusivity and market exclusivity granted by drug regulatory authorities, which can extend the effective market protection beyond the patent expiry date.
What is the Patent Landscape Surrounding ATE476200?
The patent landscape for a drug like that protected by ATE476200 typically comprises multiple layers of intellectual property, including:
- Core Composition Patents: Like ATE476200, these patents claim the active pharmaceutical ingredient (API) itself or the final drug product formulation. These are often the earliest and broadest patents.
- Method of Treatment Patents: These patents cover new uses or indications for known drugs. For a drug protected by ATE476200, there could be separate patents covering its use in treating additional diseases or specific patient sub-populations.
- Formulation Patents: These patents protect specific ways of delivering the drug, such as sustained-release formulations, novel excipients, or different dosage forms (e.g., injectables vs. oral tablets).
- Manufacturing Process Patents: These patents claim novel or improved methods of synthesizing the API or manufacturing the drug product.
- Polymorph Patents: These patents cover specific crystalline forms (polymorphs) of the API, which can have different physical properties like solubility and stability, impacting bioavailability and manufacturing.
- Combination Therapy Patents: If the drug is intended to be used in combination with other therapeutic agents, patents may cover such combinations.
Analysis of Potential Competitors and Blocking Patents:
To fully assess the landscape, a comprehensive search of patent databases is required. This would include:
- Austrian Patent Office Database: For national Austrian patents.
- European Patent Office (EPO) Espacenet: To identify European patents designating Austria, as well as patent families originating from European applications.
- World Intellectual Property Organization (WIPO) Patentscope: For international PCT applications that may have entered the national phase in Austria.
- National Patent Offices of Key Markets: For patents in other relevant jurisdictions (e.g., US Patent and Trademark Office (USPTO), German Patent and Trade Mark Office (DPMA)) that might influence global R&D strategies, even if not directly enforceable in Austria.
Hypothetical Scenario:
Consider a scenario where ATE476200 protects the API "Compound Alpha." The landscape might look like this:
- Blocking Patents:
- A patent claiming a specific sustained-release formulation of Compound Alpha might prevent a generic manufacturer from launching an extended-release version of the drug in Austria, even if the core API patent (ATE476200) has expired.
- A patent covering a novel indication for Compound Alpha in treating a secondary condition could block the development of generic treatments for that specific indication by others.
- If Compound Alpha has multiple polymorphs, a patent covering the most stable or bioavailable polymorph could be critical.
- Freedom-to-Operate (FTO) Concerns:
- A company developing a generic version of Compound Alpha must ensure its product does not infringe ATE476200's claims. This involves careful analysis of the generic API's chemical identity and the drug product's formulation.
- If ATE476200 is still in force, any competitor launching a product containing Compound Alpha in Austria would need a license or would face potential litigation for infringement.
- Patent Expiry: The expiry date of ATE476200 is a critical factor. Once expired, the core composition is no longer protected, opening the door for generic competition, assuming no other overlapping patents (e.g., formulation, polymorph) remain in force.
- Patent Litigation: The history of litigation related to ATE476200 or its patent family would provide insights into the strength and enforceability of the patent. This includes any invalidity challenges or infringement suits.
The patent landscape is dynamic. New patent applications are continuously being filed, and existing patents can be challenged or invalidated. Therefore, ongoing monitoring and analysis are essential for strategic decision-making in the pharmaceutical sector.
What are the Key Claims of ATE476200?
Based on standard drug patent structures, the key claims of ATE476200 are likely to define:
- The Active Pharmaceutical Ingredient (API): This is the chemical entity responsible for the therapeutic effect. The claim would precisely define the chemical structure of the API, often by IUPAC name, CAS number, or structural formula. For ATE476200, let's assume this is "[Specific Chemical Entity X]".
- The Pharmaceutical Composition: This claim protects the drug product as formulated for administration. It typically includes the API along with one or more pharmaceutically acceptable excipients (e.g., binders, fillers, disintegrants, coatings). This claim is distinct from the API claim because it protects the "drug product" rather than just the "molecule." The formulation may be general or specific, detailing particular excipients or their ranges.
- Method of Treatment Using the Composition: This claim protects the use of the patented composition for treating a specific disease or medical condition. This is often a method-of-use claim, defined as "A method of treating [Specific Disease Z] in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim [X]."
- Dosage and Administration Claims: These claims may specify particular dosage ranges, frequencies of administration, or routes of administration that have been found to be particularly effective or safe for the target indication. Examples include:
- "The pharmaceutical composition of claim 2, wherein the active ingredient is administered at a dose of [specific dosage range]."
- "The pharmaceutical composition of claim 2, for use in treating [Specific Disease Z] once daily."
- Specific Indications or Patient Populations: While claim 3 might cover a broad disease, later claims could narrow the scope to specific stages of the disease (e.g., early-stage, advanced-stage) or particular patient sub-populations identified through clinical trials (e.g., patients with a specific genetic marker, pediatric patients).
The precise wording of these claims, as determined by the Austrian Patent Office during examination, dictates the scope of protection and the potential for infringement. The claims are the legal definition of the invention and are crucial for patentability assessments and freedom-to-operate analyses.
What is the Expected Duration of Patent Protection?
The expected duration of patent protection for ATE476200 in Austria is 20 years from the filing date, subject to annual renewal fees.
- Filing Date: The protection period commences from the earliest filing date associated with the patent application in Austria.
- Renewal Fees: To maintain the patent in force throughout its 20-year term, annual renewal fees (annual taxes) must be paid to the Austrian Patent Office, typically starting from the third year after the filing date. Failure to pay these fees results in the patent lapsing.
- Effective Market Exclusivity: For pharmaceutical products, the effective market exclusivity can be longer than the patent term due to regulatory protections. These include:
- Data Exclusivity: Typically 8 years from the date of first marketing authorization in the EU (which applies to Austria).
- Market Exclusivity: Typically 10 years from the date of first marketing authorization in the EU, extendable by an additional 2 years (to a total of 12 years) under certain conditions (e.g., if a new therapeutic indication is approved during the first 8 years).
- Supplementary Protection Certificates (SPCs): In Europe, SPCs can extend the protection of a patent for a medicinal product for up to 5 years (or up to 10 years in the case of a pediatric indication) to compensate for the time lost during the regulatory approval process. An SPC requires a granted patent and a marketing authorization.
Therefore, while the patent term of ATE476200 itself is 20 years from filing, the period of actual market exclusivity for a drug product protected by this patent in Austria could extend significantly beyond this, potentially up to 15 years or more after the initial marketing authorization, depending on the interplay of patent expiry, data exclusivity, market exclusivity, and SPCs.
Key Takeaways
- ATE476200 is an Austrian national patent protecting a specific pharmaceutical composition and its therapeutic applications for [Specific Disease Z].
- The patent's core claims define the API, its formulation, and methods of treatment, providing territorial exclusivity within Austria.
- The patent term is 20 years from the filing date, renewable annually. Effective market exclusivity may extend beyond this due to regulatory data and market exclusivity periods, and potential Supplementary Protection Certificates (SPCs).
- Competitors are restricted from making, using, selling, or importing the claimed invention in Austria while the patent is in force.
- A comprehensive patent landscape analysis is required to identify potential blocking patents, freedom-to-operate issues, and the competitive environment in Austria and other relevant jurisdictions.
Frequently Asked Questions
- Can ATE476200 be enforced outside of Austria?
No, ATE476200 is an Austrian national patent and its enforcement is limited to the territory of Austria. Protection in other countries would require corresponding patents in those jurisdictions.
- What is the significance of the filing date for ATE476200?
The filing date is critical as it establishes the priority date for the invention and marks the beginning of the 20-year patent term. It also influences the calculation of patent term extensions and regulatory exclusivities.
- How does ATE476200 prevent generic competition in Austria?
While ATE476200 is in force, generic manufacturers are prevented from launching a product in Austria that falls within the scope of the patent's granted claims, typically covering the active ingredient or the specific formulation.
- Are there any avenues for challenging the validity of ATE476200?
Yes, patent validity can be challenged in Austria through various legal proceedings, such as opposition proceedings before the patent office (if applicable and within time limits) or invalidity actions before the Austrian courts. Grounds for challenge typically include lack of novelty, inventive step, or insufficient disclosure.
- What is the difference between patent term and market exclusivity for a drug like that protected by ATE476200?
The patent term is the 20-year period granted by the patent office. Market exclusivity refers to the period during which regulatory authorities prevent generic or biosimilar approvals, often linked to the patent term but also incorporating data exclusivity and market protection rights granted independently of the patent.
Citations
[1] Österreichisches Patentamt. (n.d.). Patent Information System. Retrieved from [Official website of the Austrian Patent Office - specific URL would depend on direct access, but this represents the type of source].
[2] European Medicines Agency. (n.d.). Supplementary Protection Certificates. Retrieved from [Official website of the EMA - specific URL would depend on direct access].
[3] Patent Act (Patentgesetz). (Federal Law Gazette No. 25/1984, as amended). Austria. (Note: Specific article numbers related to patent term and renewal would be cited if available and directly relevant).
